Airline stocks tumble amid economic concerns

Airline stocks tumble amid economic concerns


United airplanes are seen at the Newark Liberty International Airport in Newark, Unitted States on July 16, 2024. 

Jakub Porzycki | Nurphoto | Getty Images

Stock Chart IconStock chart icon

hide content

NYSE Arca Airline Index versus the S&P 500

Airlines, especially full-service carriers with big international networks, had been a bright spot thanks to strong demand and moderating domestic flight growth, but some analysts are now anticipating potential demand impacts, particularly for more price-sensitive customers ahead of the crucial spring travel season.

U.S. consumer spending fell in January for the first time in almost two years, the U.S. Commerce Department said last week. Earlier in February, its retail sales report from a month earlier showed a bigger-than-expected drop.

Read more CNBC airline news

“While we continue to remain constructive on the supply backdrop – which we still believe is favorable – our attention has shifted to what appears to be an emerging economic ‘soft patch,'” Deutsche Bank said in a note on Tuesday. “To what extent and duration are not clear at the present, however, we do think it will likely weigh on demand for air travel, particularly the domestic discretionary segment.”

The bank said it has not seen any signs of weakness in corporate or long-haul international travel.

“Business is really robust,” United Airlines CFO Mike Leskinen said at a Barclays industry conference last month. “International leisure is very strong. Domestic leisure is kind of okay. It’s fine. It’s what we expected.”



Source

Real estate could be the big winner in the private credit exodus
Business

Real estate could be the big winner in the private credit exodus

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. Barely […]

Read More
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Business

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.  The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]

Read More
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More